ADDISON, Texas, Oct. 9, 2013 /PRNewswire/ -- ULURU Inc. (OTCQB: ULUR), today announced the further expansion of the Altrazeal® international marketing network to include Croatia, Slovenia, Serbia, Montenegro, Macedonia, Bosnia, Kosovo and Albania.
Marketing and distribution agreements have been signed for this territory for the exclusive marketing and distribution of Altrazeal®. It is anticipated that Altrazeal® will be launched in these markets in the fourth quarter 2013.
Commenting on the extension of the international marketing network, Helmut Kerschbaumer, Managing Director of Altrazeal GmbH, stated, "The appointment of an exclusive marketing partner for this region is in line with our objective of marketing Altrazeal® throughout the territory. Collectively there are over 23 million people in this group of countries which presents an opportunity to generate quite significant incremental revenue. Marketing activities have commenced in preparation for the launch of Altrazeal®."
Altrazeal® is a scientifically engineered advanced wound dressing designed to incorporate the desired features and benefits of the ideal wound dressing. Altrazeal® competes in the advanced wound dressing market which, worldwide, is estimated to be $6.5 billion growing annually at 13%. Altrazeal® has demonstrated potential clinical and economic advantages in a number of chronic and acute wounds including diabetic foot ulcers, venous leg ulcers and geriatric wounds.
About ULURU Inc.:
ULURU Inc. is a specialty pharmaceutical company focused on the development of a portfolio of wound management and oral care products to provide patients and consumers improved clinical outcomes through controlled delivery utilizing its innovative Nanoflex® Aggregate technology and OraDisc transmucosal delivery system. For further information about ULURU Inc., please visit our website at www.ULURUinc.com. For further information about Altrazeal®, please visit www.Altrazeal.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended. These statements are subject to numerous risks and uncertainties, including but not limited to the launch of Altrazeal® in the territory, the commercial potential of Altrazeal® and the demonstration of cost savings and clinical benefits, and the risk factors detailed in the Company's Annual Report on Form 10-K for the year ended December 31, 2012, and other reports filed by us with the Securities and Exchange Commission.
Kerry P. Gray
President & CEO
Terry K. Wallberg
Vice President & CFO
SOURCE ULURU Inc.